Followers | 263 |
Posts | 37231 |
Boards Moderated | 1 |
Alias Born | 02/05/2003 |
Thursday, December 07, 2023 10:08:35 PM
Volume: | 290,705 |
Day Range: | 1.5211 - 1.5799 |
Bid: | 1.53 |
Ask: | 1.54 |
Last Trade Time: | 3:20:25 PM EST |
Total Trades: | 1,004 |
Recent ITRM News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2024 11:30:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/10/2024 12:04:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2024 02:15:44 PM
- Iterum Therapeutics Regains Full Nasdaq Compliance • GlobeNewswire Inc. • 11/21/2024 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 12:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 12:15:08 PM
- Iterum Therapeutics Reports Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 11/14/2024 12:00:00 PM
- Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 • GlobeNewswire Inc. • 11/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:10:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/30/2024 10:24:11 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/28/2024 10:06:08 AM
- Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections • PR Newswire (US) • 10/28/2024 09:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2024 03:20:39 PM
- Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections • GlobeNewswire Inc. • 10/25/2024 03:03:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 12:00:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/11/2024 08:01:41 PM
- Iterum Therapeutics to Present Data at IDWeek 2024 • GlobeNewswire Inc. • 10/10/2024 12:30:00 PM
- Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit • GlobeNewswire Inc. • 10/09/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/08/2024 01:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 09:20:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/30/2024 08:15:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/30/2024 11:30:02 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/24/2024 01:01:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/24/2024 12:59:25 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/23/2024 10:30:01 AM
FEATURED Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM
VOCODIA HOLDINGS INC. (OTCMKTS: VHAI) and TRACCOM INC. (OTCMKTS: TRCC) have signed an MOU to form a Joint Venture that will Revolutionize Event Monitoring with Narrative AI • VHAI • Jan 15, 2025 2:53 PM